Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Type 2 diabetes mellitus (T2DM) is a prevalent yet complex metabolic disorder that has shown a rising incidence over the past few decades. Recent research has identified flavonoids as compounds ...

Flavonoids are categorized into several subclasses based on their chemical structure ... by increasing phosphorylation of insulin receptor substrate-1 (IRS-1) and activating AMP-activated protein ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.